$61.23
-1.10-1.76%
Last update: Oct 23, 4:00 PM
Cytokinetics Inc (CYTK) Stock Price, Quote, News & History
CYTKNASDAQ
Cytokinetics reports Phase 3 results for aficamten in treating hypertrophic cardiomyopathy, targeting a Q4 FDA submission.
You can purchase shares of Cytokinetics (NASDAQ:CYTK) through any online brokerage.
Other companies in Cytokinetics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Cytokinetics has a consensus price target of $99.17.
The stock price for Cytokinetics (NASDAQ: CYTK) is $61.23 last updated October 23, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Cytokinetics.
Cytokinetics does not have any upcoming earnings scheduled.
There is no upcoming split for Cytokinetics.
Cytokinetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle...
